Document Detail

Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
MedLine Citation:
PMID:  21036768     Owner:  NLM     Status:  MEDLINE    
PATIENTS AND METHODS: We investigated 147 patients suffering from Hodgkin's disease after a follow-up of at least 5 years from the completion of CT-RT. Seventy-eight patients were submitted to ABVD-RT, 36 to VEBEP-RT and 33 to MOPP-ABVD-RT. Patients underwent spirometry, 2D-doppler echocardiography at rest, cardiopulmonary exercise test on cycloergometer and determination of cardiac output by a non invasive method.
RESULTS: Patients of the three different treatment groups showed tolerance to exercise, and oxygen consumption significantly lower than the predicted values but there were no statistically significant difference between the three groups. Nevertheless, patients treated with VEBEP and with MOPP-ABVD showed an ejection fraction at rest lower than those observed in the ABVD group and patients treated with VEBEP showed a cardiac output for oxygen uptake lower than those observed in the ABVD and MOPP-ABVD treatment groups.
CONCLUSION: These data confirm that the combination of mediastinal RT with the more commonly used polychemotherapy regimens produce late toxic effects. The lower exercise capacity seems to be due to a combination of decreased cardiac performance and impairment of ventilation. The VEBEP regimens could be potentially more toxic for the heart, probably because of the higher cumulative dose of anthracyclines.
Alessandra Busia; Alberto Laffranchi; Simonetta Viviani; Valeria Bonfante; Fabrizio Villani
Related Documents :
20066168 - Endothelial function as a possible significant determinant of cardiac function during e...
3149188 - Validation of a modified one-step rebreathing technique for measuring exercise cardiac ...
6140278 - Changes in cardiac functional capacity after coronary bypass surgery in relation to ade...
12457418 - Doppler echocardiography for the estimation of cardiac output with exercise.
8793458 - Effects of exercise and co2 inhalation on intersubject variability in ventilatory and h...
10163448 - The shape up challenge: a community-based worksite exercise competition.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  30     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-11-01     Completed Date:  2010-12-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  4381-7     Citation Subset:  IM    
UO Pneumologia e Fisiopatologia Respiratoria Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects*,  therapeutic use
Bleomycin / administration & dosage,  adverse effects
Cardiovascular Diseases / chemically induced,  etiology*,  metabolism,  physiopathology
Combined Modality Therapy / adverse effects
Cyclophosphamide / administration & dosage,  adverse effects
Dacarbazine / administration & dosage,  adverse effects
Doxorubicin / administration & dosage,  adverse effects
Epirubicin / administration & dosage,  adverse effects
Etoposide / administration & dosage,  adverse effects
Hodgkin Disease / drug therapy*,  metabolism,  physiopathology,  radiotherapy*
Lung Diseases / chemically induced,  etiology*,  metabolism,  physiopathology
Mechlorethamine / administration & dosage,  adverse effects
Middle Aged
Oxygen Consumption / drug effects
Prednisone / administration & dosage,  adverse effects
Procarbazine / administration & dosage,  adverse effects
Radiation Injuries / etiology*
Radiotherapy / adverse effects
Vinblastine / administration & dosage,  adverse effects
Vincristine / administration & dosage,  adverse effects
Young Adult
Reg. No./Substance:
11056-06-7/Bleomycin; 23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 4342-03-4/Dacarbazine; 50-18-0/Cyclophosphamide; 51-75-2/Mechlorethamine; 53-03-2/Prednisone; 56420-45-2/Epirubicin; 57-22-7/Vincristine; 671-16-9/Procarbazine; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patien...
Next Document:  NICE public health guidance: update.